Yu Dou, Eldred William D
Boston University, Program in Neuroscience, Massachusetts 02215, USA.
Vis Neurosci. 2005 Nov-Dec;22(6):825-38. doi: 10.1017/S0952523805226123.
Nitric oxide (NO) is a free radical that is important in retinal signal transduction and cyclic guanosine monophosphate (cGMP) is a critical downstream messenger of NO. The NO/cGMP signaling pathway has been shown to modulate neurotransmitter release and gap junction coupling in horizontal cells and amacrine cells, and increase the gain of the light response in photoreceptors. However, many of the mechanisms controlling the production of NO and cGMP remain unclear. Previous studies have shown activation of NO/cGMP production in response to stimulation with N-methyl-d-aspartate (NMDA) or nicotine, and the differential modulation of cGMP production by GABA(A) and GABA(C) receptors (GABA(A)Rs and GABA(C)Rs). This study used cGMP immunocytochemistry and NO imaging to investigate how the inhibitory GABAergic and glycinergic systems modulate the production of NO and cGMP. Our data show that blocking glycine receptors (GLYR) with strychnine (STRY) produced moderate increases in cGMP-like immunoreactivity (cGMP-LI) in select types of amacrine and bipolar cells, and strong increases in NO-induced fluorescence (NO-IF). TPMPA, a selective GABACR antagonist, greatly reduced the increases in cGMP-LI stimulated by STRY, but did not influence the increase in NO-IF stimulated by STRY. Bicuculline (BIC), a GABA(A)R antagonist, however, enhanced the increases in both the cGMP-LI and NO-IF stimulated by STRY. CNQX, a selective antagonist for alpha-Amino-3-hydroxy-5-methyl-4-isoxazoleproprionic acid hydrobromide/kainic acid (AMPA/KA) receptors, eliminated both the increases in cGMP-LI and NO-IF stimulated by STRY, while MK801, a selective antagonist for NMDA receptors, slightly increased the cGMP-LI and slightly decreased the NO-IF stimulated by STRY. Finally, double labeling of NO-stimulated cGMP and either GLY or GABA indicated that cGMP predominantly colocalized with GLY. Taken together, these findings support the hypothesis that GLY and GABA interact in the regulation of the NO/cGMP signaling pathway, where GLY primarily inhibits NO production and GABA has a greater effect on cGMP production. Such interacting inhibitory pathways could shape the course of signal transduction of the NO/cGMP pathway under different physiological situations.
一氧化氮(NO)是一种自由基,在视网膜信号转导中起重要作用,而环磷酸鸟苷(cGMP)是NO的关键下游信使。NO/cGMP信号通路已被证明可调节水平细胞和无长突细胞中神经递质的释放和缝隙连接耦合,并增加光感受器中光反应的增益。然而,许多控制NO和cGMP产生的机制仍不清楚。先前的研究表明,用N-甲基-D-天冬氨酸(NMDA)或尼古丁刺激可激活NO/cGMP的产生,以及GABA(A)和GABA(C)受体(GABA(A)Rs和GABA(C)Rs)对cGMP产生的差异调节。本研究使用cGMP免疫细胞化学和NO成像来研究抑制性GABA能和甘氨酸能系统如何调节NO和cGMP的产生。我们的数据表明,用士的宁(STRY)阻断甘氨酸受体(GLYR)会使某些类型的无长突细胞和双极细胞中的cGMP样免疫反应性(cGMP-LI)适度增加,而使NO诱导的荧光(NO-IF)强烈增加。TPMPA是一种选择性GABACR拮抗剂,它大大降低了STRY刺激引起的cGMP-LI增加,但不影响STRY刺激引起的NO-IF增加。然而,GABA(A)R拮抗剂荷包牡丹碱(BIC)增强了STRY刺激引起的cGMP-LI和NO-IF增加。CNQX是α-氨基-3-羟基-5-甲基-4-异恶唑丙酸氢溴酸盐/海人酸(AMPA/KA)受体的选择性拮抗剂,它消除了STRY刺激引起的cGMP-LI和NO-IF增加,而NMDA受体的选择性拮抗剂MK801则略微增加了STRY刺激引起的cGMP-LI,并略微降低了NO-IF。最后,对NO刺激的cGMP与GLY或GABA进行双重标记表明,cGMP主要与GLY共定位。综上所述,这些发现支持以下假设:GLY和GABA在NO/cGMP信号通路的调节中相互作用,其中GLY主要抑制NO的产生,而GABA对cGMP的产生有更大的影响。这种相互作用的抑制途径可能会在不同生理情况下塑造NO/cGMP途径的信号转导过程。